BioMarin Pharmaceutical: Growth Momentum Overshadowed by Pipeline Setbacks and Earnings Pressures
Apr 09, 2026 | Team Kalkine
Image source: Shutterstock
BMRN:NASDAQ
Investment Type
Large-cap
Risk Level
Action
Rec. Price (US$)
BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) is a global biotechnology firm dedicated to converting genetic insights into targeted treatments for rare and severe disorders. The company commercializes eight key products, including Vimizim, Naglazyme, Palynziq, Brineura, Aldurazyme, Roctavian, Kuvan, and Voxzogo, addressing conditions such as lysosomal storage disorders, phenylketonuria, achondroplasia, and severe hemophilia A. Roctavian is a gene therapy aimed at restoring factor VIII levels in hemophilia A patients, while Voxzogo focuses on growth-related disorders. In addition, BioMarin has a broad clinical and preclinical pipeline featuring programs such as Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701, with INZ-701 positioned as a late-stage enzyme replacement therapy for ENPP1 deficiency.
As per US Inflation Report publishedon ‘BMRN’ on Feb 27, 2026, Kalkine provided an ‘Buy’ stance on the stock at USD 61.11 based on fundamental analysis.
Enter your details below and our team will help you to decide if this product is best for you.
Disclaimer-
The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.
Past performance is not a reliable indicator of future performance.
AU
UK
US
NZ
IND
CA
-Copy_04_09_2026_21_06_37_639560.jpg)
Please wait processing your request...